Clinical Diagnosis

Product is forging a future in ocular regenerative procedures

On this week's episode of the NeuroOp Guru, Andy Lee, MD, and Elizabeth Fortin, MD, discuss Tocilizumab and the influence it can have on ophthalmic outcomes in giant cell arteritis.

For many surgeons, technology is replacing old methods , including the use of cadaver eyes.

According to Sarah Van Tassel, MD, physicians may need to recognize issues and treat patients more holistically.

Researchers in Trinity’s School of Genetics and Microbiology developed a new gene therapy, ophNdi1, that is the first of its kind to directly target mitochondrial function in cells that are malfunctioning in AMD.

Audrey R. Talley Rostov, MD, discusses how patient education and hygiene is important for a positive outcome.

According to Alyson Hall, MD, factors can include vascular dysregulation, oxidative stress, autoimmunity and cytotoxicity.

George Waring IV, MD, FACS, points out that supplementation and customized procedures are in the offing.

According to researchers, functional assessments and education are critical to an early diagnosis.

With a few key steps, surgeons can avert potential refractive surprises, and reduce postoperative dry eye for patients.

Reservoir restoration can re establish the normal anatomy and function of the conjunctiva.

By creating customized packages that incorporate the range of diagnostic and treatment options available, practices can simplify dry eye management and improve patients' outcomes.

Oyster Point Pharma Inc. today announced that the largest Medicare pharmacy benefit manager in the United States will add its varenicline solution nasal spray (Tyrvaya) for the treatment of dry eye on its Medicare Part D formularies, effective September 1.

A team of investigators has found that myopic refractive error is linked with an increased risk of primary open-angle glaucoma, and they indicate that the connection has a genetic foundation.

Zachary Elkin, MD, MPH, of NYU Langone Eye Center, advises how ophthalmologists and parents should be aware of precautions that should be taken with sports involving small balls and urges the use of protective eyewear.

Retina indications for which ranibizumab-eqrn is interchangeable include neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy, and myopic choroidal neovascularization.

A novel regimen may represent an improvement over current methods of handling postsurgical pain in procedures that require corneal epithelial debridement, according to investigators.

Symptoms in the eye may not be substantial in patients with COVID-19.

Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study.

Two studies conducted in collaboration with Orbis International explore how providing free glasses to children improves their ability to learn in school and that addressing visual impairment in children can alleviate depression and anxiety.

The doctors will join the Cataract and Primary Eye Care, Glaucoma, and Retina Services.

Several issues may restimulate the virus in those patients with prior exposure.

Behin Barahimi, MD, discusses some current trends in the treatment of dry eye disease. An oculoplastic, orbital and reconstructive surgeon, she is a member of the faculty at Vanderbilt Eye Institute.

Gareth Lema, MD, PhD, discusses an innovative eye stroke program at Mount Sinai Health System that involves collaboration among ophthalmologists, the stroke service, and emergency department physicians.

Treatment and reduces burden of care, providing a treatment option for patients diagnosed with diabetic macular edema.

According to the company, the study assesses the safety and tolerability of a single dose of CLS-AX administered to patients diagnosed with wet AMD by suprachoroidal injection.

Trial is evaluating the use of the Technolas TENEO excimer laser for vision correction surgery for hyperopia with astigmatism.

According to the company, new imaging options presenting opportunity for better outcomes for patients.

Mount Sinai study could lead to earlier and increased screening for this population to prevent blindness.

According to the company, 6-month safety and efficacy data are expected in Q1 2023. MCO-010 gene therapy reprograms healthy retinal cells to make them photosensitive.